Turner Michael K, Hooten W Michael, Schmidt John E, Kerkvliet Jennifer L, Townsend Cynthia O, Bruce Barbara K
Department of Physical Medicine and Rehabilitation, Mayo Graduate School of Medicine, Rochester, Minnesota 55905, USA.
Pain Med. 2008 Nov;9(8):979-84. doi: 10.1111/j.1526-4637.2008.00415.x. Epub 2008 Mar 11.
Vitamin D inadequacy is associated with medication refractory musculoskeletal pain and neuromuscular dysfunction. This vitamin deficiency could subsist as an unrecognized comorbid condition among patients with chronic pain. The primary objective of this study was to determine the prevalence and clinical correlates of vitamin D inadequacy in patients seeking treatment for chronic pain.
Retrospective case series.
Multidisciplinary pain rehabilitation center at a tertiary referral medical center.
The study involved 267 chronic pain patients admitted from February to December 2006.
Serum 25-hydroxyvitamin D (25[OH]D) was drawn at admission.
Patients with serum 25[OH]D levels < or=20 ng/mL were considered to have inadequate levels and those with levels >20 ng/mL were considered to have adequate levels. Upon admission, opioid intake was documented and patients completed the Short Form-36 Health Status Questionnaire.
The prevalence of vitamin D inadequacy was 26% (95% confidence interval, 20.6-31.1%). Among patients using opioids, the mean morphine equivalent dose for the inadequate vitamin D group was 133.5 mg/day compared with 70.0 mg/day for the adequate group (P = 0.001). The mean duration of opioid use for the inadequate and adequate groups were 71.1 months and 43.8 months, respectively (P = 0.023). Opioid users with inadequate levels reported worse physical functioning (P = 0.041) and health perception (P = 0.003) than opioid users with adequate levels.
The prevalence and clinical correlates identified in this pilot study provide the basis for the assertion that vitamin D inadequacy may represent an under-recognized source of nociception and impaired neuromuscular functioning among patients with chronic pain.
维生素D不足与药物难治性肌肉骨骼疼痛及神经肌肉功能障碍相关。这种维生素缺乏可能作为一种未被识别的合并症存在于慢性疼痛患者中。本研究的主要目的是确定寻求慢性疼痛治疗的患者中维生素D不足的患病率及其临床相关因素。
回顾性病例系列研究。
一所三级转诊医疗中心的多学科疼痛康复中心。
本研究纳入了2006年2月至12月收治的267例慢性疼痛患者。
入院时检测血清25-羟维生素D(25[OH]D)水平。
血清25[OH]D水平≤20 ng/mL的患者被认为维生素D水平不足,>20 ng/mL的患者被认为维生素D水平充足。入院时记录阿片类药物的使用情况,患者完成简短健康调查问卷36项(Short Form-36 Health Status Questionnaire)。
维生素D不足的患病率为26%(95%置信区间,20.6-31.1%)。在使用阿片类药物的患者中,维生素D不足组的平均吗啡等效剂量为133.5 mg/天,而充足组为70.0 mg/天(P = 0.001)。维生素D不足组和充足组的阿片类药物平均使用时长分别为71.1个月和43.8个月(P = 0.023)。维生素D水平不足的阿片类药物使用者在身体功能(P = 0.041)和健康认知(P = 0.003)方面的报告比维生素D水平充足的使用者更差。
本初步研究中确定的患病率及其临床相关因素为以下论断提供了依据,即维生素D不足可能是慢性疼痛患者中未被充分认识的伤害感受源和神经肌肉功能受损的原因。